Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J Mog

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Nature Communications|August 21, 2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigenKatharine M Wright, Sarah R DiNapoli, Michelle S Miller, et al.
Science Translational Medicine|July 10, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J Mog, Nikita Marcou, Sarah R DiNapoli, et al.
Nature Communications|September 7, 2021
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigensMichael S Hwang, Michelle S Miller, Puchong Thirawatananond, et al.
Nature|March 28, 2024
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancersTushar D Nichakawade, Jiaxin Ge, Brian J Mog, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cellsJin Liu, Yuanxuan Xia, Brian J Mog, et al.
Science (New York, N.Y.)|March 2, 2021
Targeting a neoantigen derived from a common <i>TP53</i> mutationEmily Han-Chung Hsiue, Katharine M Wright, Jacqueline Douglass, et al.
Science Immunology|March 2, 2021
Bispecific antibodies targeting mutant <i>RAS</i> neoantigensJacqueline Douglass, Emily Han-Chung Hsiue, Brian J Mog, et al.
Nature Cancer|December 22, 2025
TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancersJiaxin Ge, Joshua Urban, Sarah R DiNapoli, et al.
The Journal of Clinical Investigation|January 16, 2026
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirementsSarah R DiNapoli, Katharine M Wright, Brian J Mog, et al.
Nature Communications|February 10, 2026
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Gergis, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Nature Communications|August 21, 2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigenKatharine M Wright, Sarah R DiNapoli, Michelle S Miller, et al.
Science Translational Medicine|July 10, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J Mog, Nikita Marcou, Sarah R DiNapoli, et al.
Nature Communications|September 7, 2021
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigensMichael S Hwang, Michelle S Miller, Puchong Thirawatananond, et al.
Nature|March 28, 2024
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancersTushar D Nichakawade, Jiaxin Ge, Brian J Mog, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cellsJin Liu, Yuanxuan Xia, Brian J Mog, et al.
Science (New York, N.Y.)|March 2, 2021
Targeting a neoantigen derived from a common <i>TP53</i> mutationEmily Han-Chung Hsiue, Katharine M Wright, Jacqueline Douglass, et al.
Science Immunology|March 2, 2021
Bispecific antibodies targeting mutant <i>RAS</i> neoantigensJacqueline Douglass, Emily Han-Chung Hsiue, Brian J Mog, et al.
Nature Cancer|December 22, 2025
TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancersJiaxin Ge, Joshua Urban, Sarah R DiNapoli, et al.
The Journal of Clinical Investigation|January 16, 2026
Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirementsSarah R DiNapoli, Katharine M Wright, Brian J Mog, et al.
Nature Communications|February 10, 2026
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Gergis, et al.
Pageof 3